View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Accelerating Clinical Trials
December 21, 2020updated 06 Jan 2021 10:09am

The benefit of running clinical trials in Asia-Pacific for biotech companies

According to Frost & Sullivan, the CRO market is forecast to grow to US$ 71.7billion by 2024 (+8% CAGR 19-24F). As biopharma companies continue to externalise R&D operations with a higher focus on the Asia-Pacific region, the CRO market in the region is forecast to grow at double the global rate, at a compound annual rate of +15%  between 2019 and 2024.

Free Whitepaper
img

Evolution of clinical trials in the Asia Pacific region compared to the US and the EU5

Over the last five years, the global clinical trial landscape has been transformed. Between 2017 and 2020, 70,000 new clinical trials were registered across the APAC region, the US and the EU5. The APAC region contributed more than 50% of these trials and saw the most growth. APAC, especially China, is emerging as the hot spot for conducting clinical trials. This whitepaper takes a deep dive into why China has been attracting more foreign biopharma companies in recent years. It presents an in-depth analysis of the evolution of clinical trials in the APAC region compared to the US and EU5.
by Novotech
Enter your details here to receive your free Whitepaper.

One of the reasons biopharma companies are turning to the Asia-Pacific region is that running trials in traditional locations, such as North America and Western Europe, is becoming more challenging.

According to GlobalData, the median number of patients recruited in oncology clinical trials involving sites in the Asia-Pacific region was over 40% higher than the global median (2018-2019 trials). As study protocols and designs become increasingly complex, so does patient recruitment. Asia, with its large treatment-naïve population pool and low trial concentration has become a preferred destination to accelerate subject recruitment for the most complex clinical trials. While Australia and New Zealand are preferred locations to run early-phase trials, sponsors often look to Asia for large, late-phase clinical studies.

Australia and Asia have become destinations of choice for biopharma clinical trials. This is mainly because of its large patient pool, lower trial density and so lower risk of competing trials, the high quality of medical facilities, government financial incentives for clinical trials, lower costs, and the strategic importance of Asian consumer markets. Moreover, a US Investigational New Drug (IND) submission is not necessary to initiate first-in-human (FIH) clinical trials in Australia.

Dr Simone Flight, principal consultant at Novotech Biodesk said: “Biotechnology companies can initiate a clinical trial in Australia in parallel to the preparation of a US IND submission, often commencing dosing within a single review cycle of six-to-eight weeks from submission.”

Moreover, most Asian countries lack systematic reimbursement of standard of care which means clinical trials are often the only channel that patients can access novel treatments. This ultimately stimulates recruitment rates and encourages patient adherence to research therapies.

In an outsourced CRO model, working with a local, regional team can be the key to success. A regional CRO provides the local expertise which supports sponsors’ ability to quickly activate sites and get patients enrolled. A flat team structure also facilitates communication between the CRO and the sponsor as well as decision-making, and to accelerate escalation when issues arise.

Also, having staff located near the study site, and understanding the culture and language makes a huge difference in terms of a study’s success rate.

Related Companies

Free Whitepaper
img

Evolution of clinical trials in the Asia Pacific region compared to the US and the EU5

Over the last five years, the global clinical trial landscape has been transformed. Between 2017 and 2020, 70,000 new clinical trials were registered across the APAC region, the US and the EU5. The APAC region contributed more than 50% of these trials and saw the most growth. APAC, especially China, is emerging as the hot spot for conducting clinical trials. This whitepaper takes a deep dive into why China has been attracting more foreign biopharma companies in recent years. It presents an in-depth analysis of the evolution of clinical trials in the APAC region compared to the US and EU5.
by Novotech
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena